With 500 billion won in its war chest, LigaChem Biosciences to tout its 'two-track' strategy in Europe

[Financial News] LigaChem Biosciences is aiming for additional technology transfers in Europe, touting its ConjuALL ADC platform, whose efficacy and safety have been confirmed in clinical trials conducted by partners.
LigaChem Biosciences said it would step up its global business development (BD) activities by attending two events in succession: BIO-Europe 2026, Europe's largest biopharma partnering event, taking place in Cologne, Germany, from the 9th to the 11th (local time), and the Jefferies Global Healthcare Conference, taking place in London, UK, from the 16th to the 19th.
The ConjuALL platform has recently demonstrated its competitiveness through data from partners' clinical trials. Leading examples are ConjuALL-based assets being developed by IKSUDA Therapeutics, including the HER2 ADC (antibody-drug conjugate) IKS014 and the CD19 ADC IKS03.
LigaChem Biosciences is aggressively expanding its pipeline by discovering new candidates while also accelerating its in-house development efforts by directly conducting clinical trials of key assets.
At BIO-Europe 2026, the company will hold one-on-one partnering meetings with numerous global pharmaceutical companies. It plans to discuss licensing its own pipeline candidates in clinical and preclinical stages, as well as licensing opportunities for its next-generation ADC platform. It will also present new pipeline candidates based on its next-generation DAR1 platform at these events.
At the Jefferies Global Healthcare Conference, it will then present its 'two-track' strategy of pursuing in-house development alongside partnering to global institutional investors and business development representatives from pharmaceutical companies. LigaChem Biosciences secured funding worth 500 billion won in July from sources including the National Growth Fund, and is directly conducting late-stage clinical trials of its key pipeline candidates.
Jeiwook Chae, senior vice president at LigaChem Biosciences, said, "Global pharmaceutical companies continue to show strong interest in the ADC field, and the competitiveness of the ConjuALL platform is being demonstrated by data from our partners' clinical trials." He added, "Through these events, we will accelerate technology transfer discussions and further expand partnership opportunities."
  
[email protected] Jung Myung-jin, Reporter